Devyser Diagnostics AB
STO:DVYSR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Devyser Diagnostics AB
Revenue
Devyser Diagnostics AB
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
Devyser Diagnostics AB
STO:DVYSR
|
Revenue
kr250.5m
|
CAGR 3-Years
26%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Revenue
kr1.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Revenue
kr1.2B
|
CAGR 3-Years
47%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Revenue
kr3.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
21%
|
CAGR 10-Years
16%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Revenue
kr28.2B
|
CAGR 3-Years
15%
|
CAGR 5-Years
13%
|
CAGR 10-Years
24%
|
|
|
BioArctic AB
STO:BIOA B
|
Revenue
kr2B
|
CAGR 3-Years
106%
|
CAGR 5-Years
100%
|
CAGR 10-Years
N/A
|
|
Devyser Diagnostics AB
Glance View
Devyser Diagnostics AB engages in the development, manufacture and sale of kits for genetic testing in routine diagnostics. The company is headquartered in Hagersten, Stockholm. The company went IPO on 2021-12-10. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The firm has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnostics’ products are sold directly to the end customer or through hired distributors. The firm provides its products in more than 45 countries.
See Also
What is Devyser Diagnostics AB's Revenue?
Revenue
250.5m
SEK
Based on the financial report for Dec 31, 2025, Devyser Diagnostics AB's Revenue amounts to 250.5m SEK.
What is Devyser Diagnostics AB's Revenue growth rate?
Revenue CAGR 5Y
31%
Over the last year, the Revenue growth was 15%. The average annual Revenue growth rates for Devyser Diagnostics AB have been 26% over the past three years , 31% over the past five years .
